DRAK2 Antibody
- SPECIFICATION
- CITATIONS
- PROTOCOLS
- BACKGROUND
Application ![]()
| WB, ICC, E |
---|---|
Primary Accession | O94768 |
Other Accession | AB011421, 3834355 |
Reactivity | Human |
Host | Rabbit |
Clonality | Polyclonal |
Isotype | IgG |
Calculated MW | 42344 Da |
Application Notes | DRAK2 antibody can be used for detection of DRAK2 by Western blot 0.5 µg/mL. An approximately 45 kDa band can be detected. Antibody can also be used for immunocytochemistry starting at 10 µg/mL. |
Gene ID | 9262 |
---|---|
Other Names | DRAK2 Antibody: DRAK2, DRAK2, DAP kinase-related apoptosis-inducing protein kinase 2, serine/threonine kinase 17b |
Target/Specificity | STK17B; It has no cross responses to DAP or ZIP kinases. The approximately 70 kDa band is probably non-related to DRAK2 although it is peptide blockable. |
Reconstitution & Storage | DRAK2 antibody can be stored at 4℃ for three months and -20℃, stable for up to one year. As with all antibodies care should be taken to avoid repeated freeze thaw cycles. Antibodies should not be exposed to prolonged high temperatures. |
Precautions | DRAK2 Antibody is for research use only and not for use in diagnostic or therapeutic procedures. |
Name | STK17B |
---|---|
Synonyms | DRAK2 |
Function | Phosphorylates myosin light chains (By similarity). Acts as a positive regulator of apoptosis. |
Cellular Location | Nucleus. Cell membrane. Endoplasmic reticulum-Golgi intermediate compartment. Note=Colocalizes with STK17B at the plasma membrane. |
Tissue Location | Highly expressed in placenta, lung, pancreas. Lower levels in heart, brain, liver, skeletal muscle and kidney |

Thousands of laboratories across the world have published research that depended on the performance of antibodies from Abcepta to advance their research. Check out links to articles that cite our products in major peer-reviewed journals, organized by research category.
info@abcepta.com, and receive a free "I Love Antibodies" mug.
Provided below are standard protocols that you may find useful for product applications.
Background
DRAK2 Antibody: Apoptosis is mediated by death domain containing adapter molecules and a caspase family of proteases. Certain serine/threonine protein kinases, such as ASK-1 and RIP, are mediators of apoptosis. Two novel serine/threonine kinases that induce apoptosis were recently identified and designated DRAK1 and DRAK2 (for DAP kinase-related apoptosis-inducing protein kinases). DRAKs contain an N-terminal kinase domain and a C-terminal regulation domain. Overexpression of DRAK2 induces apoptosis. DRAKs have high sequence homology to DAP and ZIP kinases, and they represent a novel family of serine/threonine kinases, which mediates apoptosis through their catalytic activities. DRAK2 is located in nucleus and the messenger RNA was ubiquitously expressed in human tissues.
References
Sanjo H, Kawai T, Akira S. DRAKs, novel serine/threonine kinases related to death-associated protein kinase that trigger apoptosis. J Biol Chem 1998;273:29066-71 (RD1299)

If you have used an Abcepta product and would like to share how it has performed, please click on the "Submit Review" button and provide the requested information. Our staff will examine and post your review and contact you if needed.
If you have any additional inquiries please email technical services at tech@abcepta.com.